Divestiture, Service Deployment, Executive Promotion, Updated Outlook, and Designation Granted-Research Report on Endo, ARIAD,

  Divestiture, Service Deployment, Executive Promotion, Updated Outlook, and
Designation Granted-Research Report on Endo, ARIAD, Align Technology, PAREXEL,
                          and The Medicines Company

PR Newswire

NEW YORK, January 16, 2014

NEW YORK, January 16, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Endo
Health Solutions, Inc. (NASDAQ: ENDP), ARIAD Pharmaceuticals, Inc. (NASDAQ:
ARIA), Align Technology, Inc. (NASDAQ: ALGN), PAREXEL International
Corporation (NASDAQ: PRXL), and The Medicines Company (NASDAQ: MDCO). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Endo Health Solutions, Inc. Research Report

On January 9, 2014, Endo Health Solutions, Inc. (Endo) announced that it has
entered into a definitive agreement to sell its HealthTronics business to
Altaris Capital Partners, LLC (Altaris) for an upfront cash payment of $85
million, subject to cash and other working capital adjustments. Additionally,
Endo stated that it will receive rights to additional cash payments of up to
$45 million based on the future operating performance of HealthTronics for a
total consideration of up to $130 million. "The divestiture of HealthTronics
enables us to focus more sharply on achieving our objective of building Endo
into a leading product-based specialty healthcare company," said Rajiv De
Silva, President and CEO of Endo. "I am pleased that the agreement with
Altaris will provide an opportunity for the employees of HealthTronics to join
an organization that will focus on growing this leading provider of products
and services to U.S.-based Urologists." The Company added that it expects the
transaction to close in Q1 2014. The Full Research Report on Endo Health
Solutions, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/059c_ENDP

--

ARIAD Pharmaceuticals, Inc. Research Report

On January 13, 2014, ARIAD Pharmaceuticals, Inc. (ARIAD) reported that it has
selected Biologics, Inc. (Biologics) to be the sole specialty pharmacy
provider of Iclusig (ponatinib) as well as manager of its Patient Access and
Support Services (ARIAD PASS) program. "We believe Biologics' approach to
patient care and expertise within oncology will deliver the best value and
experience to our patients and providers," said Marty J. Duvall, Executive
Vice President and Chief Commercial Officer at ARIAD. "Our primary objective
is to make sure that our patients can access, afford and adhere to this
important cancer medicine." The Company further notified that its decision to
utilize a close distribution network with Biologics was made to ensure a
high-touch care model for patients on Iclusig, as well as to increase
efficiencies as the product is made commercially available in the US in
January 2014. The Full Research Report on ARIAD Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/161c_ARIA

--

Align Technology, Inc. Research Report

On January 13, 2014, Align Technology, Inc. (Align Technology) announced the
promotion of Raphael S. Pascaud to the position of Vice President
International, wherein he will report directly to Thomas M. Prescott,
President and CEO of the Company. According to the Align Technology, Pascaud
in his new role succeeded Richard Towney, who resigned at the end of 2013.
"Raphael has been a very effective leader of our Europe, Middle East, and
Africa Region for several years, driving continued growth and expansion in
this largest component of our international business," said Prescott. "During
his tenure at Align, Raphael has been recognized as a valuable member of the
senior management team and I am very pleased to have him take on this new role
and level of responsibility. We have a tremendous opportunity to extend our
growth outside of North America and I look forward to Raphael extending his
enthusiasm and expertise to our Asia Pacific and Latin America sales and
marketing efforts." The Full Research Report on Align Technology, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/69b3_ALGN

--

PAREXEL International Corporation Research Report

On January 13, 2014, PAREXEL International Corporation (PAREXEL) announced its
operational and financial outlook for Q2 FY 2014 (period ended December 31,
2013), and full-year FY 2014 (period ending June 30, 2014).The Company
informed that it expects to report a net book-to-bill ratio in excess of 1.3
in Q2 FY 2014. Meanwhile, PAREXEL expects its revenues to range between $480
million to $485 million, and GAAP EPS to be between $0.48 and $0.50 during the
quarter. For full-year FY 2014, the Company expects revenues to be between
$1.895 - $1.925 billion, and GAAP EPS to range between $1.97 and $2.11. The
Full Research Report on PAREXEL International Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/067b_PRXL

--

The Medicines Company Research Report

On January 13, 2014, The Medicines Company (Medicines Co.) announced that the
U.S. Food and Drug Administration (FDA) has designated Carbavance as a
Qualified Infectious Disease Product (QIDP). According to the Company, the
QIDP designation for Carbavance, a novel class of beta-lactamase inhibitors
designed by Medicines Co.'s subsidiary, Rempex Pharmaceuticals, qualifies the
investigational agent for priority review by the FDA, for the FDA's "fast
track" status, and an additional five years of exclusivity upon approval of
the product for intravenous use in six indications. "We believe a priority
review and approval will help us bring the novel Carbavance to patients with
serious gram negative infections more quickly," said Clive Meanwell, MD, PhD,
Chairman and CEO of Medicines Co. "Advancing Carbavance serves our purpose to
save lives, alleviate suffering, and contribute to the economics of healthcare
by serving leading hospitals." The Full Research Report on The Medicines
Company - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5a84_MDCO

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)